Despite support from the AAP, some doctors and organizations, including eating disorder advocacy groups, have argued that there could be mental health risks to making GLP-1s available to adolescents, such as the increased risk of developing disordered eating and worsening stigma around weight
Cognition Animal studies suggested the GLP-1 RAs may improve cognition, but results in humans have been inconclusive
This distinction matters when you're comparing a compounded semaglutide preparation at $199/month to an FDA-approved Wegovy injection at roughly $1,300+ per month retail
The FDA proposed to exclude semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and liraglutide (Saxenda, Victoza), popular glucagon-like peptide-1 (GLP-1) medications, from the 503B bulk list, citing a lack of clinical need for outsourcing facilities to compound these medications from bulk drug substances